Eli Lilly shutters the last PhIII sola study, certain of failure
Eli Lilly has taken another big reverse step in its retreat from solanezumab, the Alzheimer’s drug once considered the company’s lottery ticket in R&D. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
